Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | enhancer of zeste 2 polycomb repressive complex 2 subunit | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | histone lysine N methyltransferase Ez | Get druggable targets OG5_129164 | All targets in OG5_129164 |
Schistosoma mansoni | enhancer of zeste ezh | Get druggable targets OG5_129164 | All targets in OG5_129164 |
Loa Loa (eye worm) | SET domain-containing protein | Get druggable targets OG5_129164 | All targets in OG5_129164 |
Brugia malayi | SET domain containing protein | Get druggable targets OG5_129164 | All targets in OG5_129164 |
Echinococcus multilocularis | histone lysine N methyltransferase E(z) | Get druggable targets OG5_129164 | All targets in OG5_129164 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | SET domain-containing protein | 0.0114 | 0.5 | 0.5 |
Echinococcus granulosus | histone lysine N methyltransferase Ez | 0.0114 | 0.5 | 0.5 |
Echinococcus multilocularis | histone lysine N methyltransferase E(z) | 0.0114 | 0.5 | 0.5 |
Schistosoma mansoni | enhancer of zeste ezh | 0.0114 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2500 nM | BindingDB_Patents: Inhibition Assay. Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 µL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 µM final concentration of SAH and negative control (0% inhibition standard) contained 1 µL of DMSO. Compound 75 was then incubated for 30 minutes with 40 µL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 µL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | ChEMBL. | No reference |
IC50 (binding) | = 4100 nM | BindingDB_Patents: Inhibition Assay. Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 µL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 µM final concentration of SAH and negative control (0% inhibition standard) contained 1 µL of DMSO. Compound 75 was then incubated for 30 minutes with 40 µL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 µL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | ChEMBL. | No reference |
IC50 (binding) | = 7180 nM | BindingDB_Patents: Inhibition Assay. Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 µL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 µM final concentration of SAH and negative control (0% inhibition standard) contained 1 µL of DMSO. Compound 75 was then incubated for 30 minutes with 40 µL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 µL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | ChEMBL. | No reference |
IC50 (binding) | = 7560 nM | BindingDB_Patents: Inhibition Assay. Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 µL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 µM final concentration of SAH and negative control (0% inhibition standard) contained 1 µL of DMSO. Compound 75 was then incubated for 30 minutes with 40 µL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 µL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | ChEMBL. | No reference |
IC50 (binding) | = 8950 nM | BindingDB_Patents: Inhibition Assay. Compound 75 was serially diluted 3 fold in DMSO for 10 points and 1 µL was plated in a 384 well microtiter plate. Positive control (100% inhibition standard) was 100 µM final concentration of SAH and negative control (0% inhibition standard) contained 1 µL of DMSO. Compound 75 was then incubated for 30 minutes with 40 µL per well of EZH2 wild-type and mutants at 8 nM in pH 7.6 assay buffer (20 mM BICINE, 100 mM KCl, 1 mM DTT, 0.002% Tween 20, 0.005% BSG). A substrate mix at 10 µL per well was added which contained 5-adenosylmethionine-Cl (SAM) at 150 nM and tritiated SAM at 100 nM, and biotinylated oligonucleosome at 150 nM in pH 7.6 assay buffer. Quenched enzyme reaction was transferred to a streptavidin-coated Flashplate (Perkin Elmer, catalog number SMP410), allowed to bind for one hour, and detected on a TopCount NXT HTS (Perkin Elmer). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.